Skip to main content
. Author manuscript; available in PMC: 2021 Sep 28.
Published in final edited form as: Cancer Immunol Res. 2020 Jan 17;8(3):345–355. doi: 10.1158/2326-6066.CIR-19-0517

Figure 1. In vivo IR700 fluorescence imaging of MC38-luc, LL/2, and MOC1 tumors after injection of anti-CD25-IR700.

Figure 1.

A. Real-time In vivo anti-CD25-IR700 fluorescence imaging of tumor-bearing mice at the indicated timepoints. The yellow arrows indicate the tumor locations. B. Quantitative analysis of mean fluorescence intensity in MC38-luc, LL/2, and MOC1 tumors (n=5/group, mean+/− SEM). *p<0.05, MC38-luc vs. MOC1 tumors, Tukey-Kramer test; **p<0.05, LL/2 vs. MOC1 tumors, Tukey-Kramer test. C. Quantitative analysis of target-to-background ratio in MC38-luc, LL/2, and MOC1 tumors (n=5/group, mean+/− SEM). *p<0.05, MC38-luc vs. MOC1 tumors, Tukey-Kramer test; **p<0.05, LL/2 vs. MOC1 tumors, Tukey-Kramer test.